CoChat

PSNCBAM‐1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats

Open access
Horswill, J G, Bali, U, Shaaban, S, Keily, J F, Jeevaratnam, P, Babbs, A J, Reynet, C, Wong Kai In, P · 2007 · British Journal of Pharmacology
Cited by 175

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background and purpose: Rimonabant (Acomplia TM, SR141716A), a cannabinoid CB 1 receptor inverse agonist, has recently been approved for the treatment of obesity. There are, however, concerns regarding its side effect profile. Developing a CB 1 antagonist with a different pharmacological mechanism may lead to a safer alternative. To this end we have screened a proprietary small molecule library and have discovered a novel class of allosteric antagonist at CB 1 receptors. Herein, we have characterized an optimized prototypical molecule, PSNCBAM‐1, and its hypophagic effects in vivo. Experimental approach: A CB 1 yeast reporter assay was used as a primary screen. PSNCBAM‐1 was additionally characterized in [35 S]‐GTPγS, cAMP and radioligand binding assays. An acute rat feeding model was used to evaluate its effects on food intake and body weight in vivo. Key results: In CB 1 receptor yeast reporter assays, PSNCBAM‐1 blocked the effects induced by agonists such as CP55,940, WIN55212‐2, anandamide (AEA) or 2‐arachidonoyl glycerol (2‐AG). The antagonist characteristics of PSNCBAM‐1 were confirmed in [35 S]‐GTPγS binding and cAMP assays and was shown to be non‐competitive by Schild analyses. PSNCBAM‐1 did not affect CB 2 receptors. In radioligand binding assays, PSNCBAM‐1 increased the binding of [3 H]CP55,940 despite its antagonist effects. In an acute rat feeding model, PSNCBAM‐1 decreased food intake and body weight. Conclusions and implications: PSNCBAM‐1 exerted its effects through selective allosteric modulation of the CB 1 receptor. The acute effects on food intake and body weight induced in rats provide a first report of in vivo activity for an allosteric CB 1 receptor antagonist. British Journal of Pharmacology (2007) 152, 805–814; doi:10.1038/sj.bjp.0707347; published online 25 June 2007

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707347

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 175

Metadata

Authors
Horswill, J. G., Bali, U., Shaaban, S., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., & Wong Kai In, P.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-11
Volume
152
Issue
5
Pages
805-814
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1880519341
Cited by
175
References
6
FWCI
4.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.